GLC756

GLC756 is a small molecule drug developed as a putative antiglaucoma agent. It is a novel octahydrobenzo[g]quinoline derivative that acts as a dopamine D2 receptor agonist and a dopamine D1 receptor antagonist. Its mechanism involves blocking dopamine-sensitive adenylate cyclase (D1 antagonist action) and stimulating dopamine D2 receptor activity. Preclinical and early clinical studies indicated that GLC756 lowers intraocular pressure, inhibits pro-inflammatory cytokine (TNF-α) release, increases cellular cAMP, and exerts antiproliferative and anti-inflammatory effects on ocular cells. Despite showing early promise, its development was discontinued after reaching phase 1. The originator and main developer is Novartis. Its primary indication was glaucoma and related ocular inflammatory processes[1][2][3][4][5][7].